Kevin Sayer sold his first glucose sensor in 1994. More than twenty years later, the chief executive of Dexcom (NSDQ:DXCM) still believes that glucose-monitoring technology can transform the way patients manage their diabetes. This week, Dexcom won FDA approval for its latest continuous glucose monitor. The G6 system is the first of the company’s that does […]
Insulet
Insulet nabs spot as in-network provider with UnitedHealthcare
Insulet (NSDQ:PODD) and UnitedHealthcare (NYSE:UNH) inked a new network relationship last week, giving people enrolled in UnitedHealthcare’s commercial and Medicaid plans in-network coverage for Insulet’s Omnipod insulin delivery device. “Through this new relationship, we are working together to help people access the insulin management technology they need to effectively manage their diabetes,” the companies wrote in a […]
Insulet beats the Street with Q4, FY17 sales
Insulet (NSDQ:PODD) reported yesterday that the insulin delivery device-maker topped sales expectations on Wall Street for its fourth quarter and full-year financial results, but missed earnings estimates. The Billerica, Mass.-based company reeled in losses, posting -$6.9 million on sales of $130.5 million for the 3 months ended Dec. 31, for sales growth of 26% compared with […]
Insulet’s closed-loop insulin delivery algorithm succeeds in feasibility study
The algorithm used in Insulet‘s (NSDQ:PODD) closed-loop insulin delivery system performed well in a 58-patient safety and feasibility study, according to a study published today in Diabetes Technology & Therapeutics. Insulet’s device, which is still in development, combines an insulin dosing algorithm, the OmniPod insulin patch pump and Dexcom‘s (NSDQ:DXCM) continuous glucose monitor into one system […]
Insulet settles investor suit for $20m
Insulet (NSDQ:PODD) plans to fork over $19.5 million to settle a class action lawsuit brought by the Arkansas Teacher Retirement System, the City of Bristol Pension Fund and the City of Omaha Police and Fire Retirement System, according to court documents. The lawsuit alleged that Insulet misrepresented the success of its OmniPod Eros roll-out in 2013, which eventually […]
Ascensia inks global distro sale with Insulet for blood glucose monitor
Ascensia Diabetes Care has expanded its partnership with Insulet (NSDQ:PODD) to include a global commercial deal. The two companies inked a world-wide development agreement in June last year to connect Ascensia’s Contour Next One blood glucose monitor with Insulet’s next-gen Omnipod system, Omnipod Dash. According to the terms of the non-exclusive commercial deal, Insulet plans to distribute […]
Insulet lands Medicare Part D coverage for Omnipod insulin delivery system
The Centers for Medicare and Medicaid Services issued guidance today noting that Insulet‘s (NSDQ:PODD) Omnipod tubeless insulin delivery device can be covered by the Medicare Part D prescription drug program. The Billerica, Mass.-based company estimated that its latest reimbursement win extends access to the Omnipod system to 450,000 people with Type I diabetes across the U.S. […]
These 10 medtech companies care a lot about research
Among the world’s largest medtech companies, these 10 spent the largest portion of their budgets on research and development. So what have they produced? Every year, Medical Design & Outsourcing pulls financial regulatory filings and reaches out to major, companies in some cases to create a list of the 100 largest medical device companies in […]
Insulet up-sizes and prices $350m private placement
Insulet (NSDQ:PODD) up-sized the private placement that it announced yesterday, citing strong investor demand. The Billerica, Mass.-based company said today it plans to offer $350 million in convertible senior notes due in 2024, up from $300 million. The notes have an annual interest rate of 1.375% and will mature on Nov. 15, 2024, according to Insulet. […]
Insulet to offer $300m in senior convertible notes as part of private placement
Insulet (NSDQ:PODD) said today that it plans to offer $300 million in convertible senior notes due in 2024 as part of a private placement. The Billerica, Mass.-based company is also slated to give initial purchasers an option to buy an additional $45 million in notes. Insulet said it plans to use the offering’s net proceeds for […]
